Roche’s subcutaneous Tecentriq meets Phase III NSCLC co-primary endpoints
In the trial, Tecentriq’s subcutaneous formulation safety profile was in line with that of IV Tecentriq.

In the trial, Tecentriq’s subcutaneous formulation safety profile was in line with that of IV Tecentriq.
The LOTIS-7 Phase Ib clinical trial will include multiple arms in dose escalation and dose expansion parts.
Implementation of Vault EDC will enable SGS to translate complex protocols into user-friendly casebook designs.
The trial will analyse the safety, tolerability, and pharmacokinetics of MTX-005 in up to 56 subjects.
The GBM AGILE trial is currently underway at 44 clinical centres in the US and Canada.
Subject dosing in the trial to assess safety and tolerability of the vaccine will begin in January next year.
Semorinemab was well-tolerated and had a tolerable safety profile in the Phase II trial.
The safety profile of the drug in the Phase III BELINDA trial was in line with the already reported data.
Thank you for subscribing to Clinical Trials Arena